Myriad Genetics, Inc. has disclosed a cybersecurity incident that occurred on November 2, 2026, revealing unauthorized access to its information technology network. This incident has led the company to temporarily suspend its testing operations and order management systems while it assesses the situation and implements remedial measures.

Upon discovering the breach, Myriad initiated its incident response procedures to contain the unauthorized activity and evaluate the nature and scope of the incident. The company has engaged external experts to assist in the investigation, which is ongoing. As of the filing date, Myriad has stated that most of its systems have returned to normal operations and does not believe that the incident will have a material adverse effect on its business.

Background

Myriad Genetics, Inc. operates in the biotechnology sector, specifically categorized under In Vitro & In Vivo Diagnostic Substances (SIC 2835). The company is listed on the Nasdaq under the ticker symbol MYGN. Myriad is known for its genetic testing services and has been a significant player in the diagnostics market.

What the Filing Says

The company’s recent filing indicates, "On November 2, 2026, Myriad Genetics, Inc. detected unauthorized access within its information technology network environment... The full scope of unauthorized access remains under investigation, including assessing whether any patient records were accessed on systems that contain patient information."

Impact

This incident may affect various stakeholders, including patients whose records could potentially be compromised, healthcare providers relying on Myriad's testing services, and investors monitoring the company's operational stability and cybersecurity measures. The biotech industry at large may also face increased scrutiny regarding data security practices.

What's Next

The filing does not say what happens next.